Back to Journals » Lung Cancer: Targets and Therapy » Volume 8 » default

Lung Cancer: Targets and Therapy


Archive: Volume 8, 2017

Bevacizumab in the treatment of NSCLC: patient selection and perspectives

Russo AE, Priolo D, Antonelli G, Libra M, Mccubrey JA, Ferraù F

Lung Cancer: Targets and Therapy 2017, 8:259-269

Published Date: 14 December 2017

65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer

Schuette W, Schneider CP, Engel-Riedel W, Schumann C, Kohlhaeufl M, Serke MHU, Hoeffken G, Kortsik C, Reck M

Lung Cancer: Targets and Therapy 2017, 8:217-229

Published Date: 6 November 2017

nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy

Thomas M, Spigel DR, Jotte RM, McCleod M, Socinski MA, Page RD, Gressot L, Knoble J, Juan O, Morgensztern D, Isla D, Kim ES, West H, Ko A, Ong TJ, Trunova N, Gridelli C

Lung Cancer: Targets and Therapy 2017, 8:207-216

Published Date: 30 October 2017

Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan

Isobe H, Mori K, Minato K, Katsura H, Taniguchi K, Arunachalam A, Kothari S, Cao X, Kato T

Lung Cancer: Targets and Therapy 2017, 8:191-206

Published Date: 24 October 2017

EGFR T790M: revealing the secrets of a gatekeeper

Ko B, Paucar D, Halmos B

Lung Cancer: Targets and Therapy 2017, 8:147-159

Published Date: 9 October 2017

Proton beam therapy in non-small cell lung cancer: state of the art

Harada H, Murayama S

Lung Cancer: Targets and Therapy 2017, 8:141-145

Published Date: 23 August 2017

Clinical staging of malignant pleural mesothelioma: current perspectives

Bonomi M, De Filippis C, Lopci E, Gianoncelli L, Rizzardi G, Cerchiaro E, Bortolotti L, Zanello A, Ceresoli GL

Lung Cancer: Targets and Therapy 2017, 8:127-139

Published Date: 18 August 2017

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy

Santarpia M, Liguori A, Karachaliou N, Gonzalez-Cao M, Daffinà MG, D'Aveni A, Marabello G, Altavilla G, Rosell R

Lung Cancer: Targets and Therapy 2017, 8:109-125

Published Date: 18 August 2017

Chronic obstructive pulmonary disease in patients with lung cancer: prevalence, impact and management challenges

Spyratos D, Papadaki E, Lampaki S, Kontakiotis T

Lung Cancer: Targets and Therapy 2017, 8:101-107

Published Date: 7 August 2017

New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer

Niki M, Yokoi T, Kurata T, Nomura S

Lung Cancer: Targets and Therapy 2017, 8:91-99

Published Date: 3 August 2017

New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab

Seetharamu N, Preeshagul IR, Sullivan KM

Lung Cancer: Targets and Therapy 2017, 8:67-78

Published Date: 13 July 2017

Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity

Cobo M, Gutiérrez V, Villatoro R, Trigo JM, Ramos I, López O, Ruiz M, Godoy A, López I, Arroyo M

Lung Cancer: Targets and Therapy 2017, 8:57-66

Published Date: 12 July 2017

Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives

Rossi G, Jocollé G, Conti A, Tiseo M, Zito Marino F, Donati G, Franco R, Bono F, Barbisan F, Facchinetti F

Lung Cancer: Targets and Therapy 2017, 8:45-55

Published Date: 7 July 2017

A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma

Jamil MO, Jerome MS, Miley D, Selander KS, Robert F

Lung Cancer: Targets and Therapy 2017, 8:39-44

Published Date: 12 June 2017

Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma

Thakur MK, Wozniak AJ

Lung Cancer: Targets and Therapy 2017, 8:13-19

Published Date: 13 February 2017